https://www.investors.com/news/technology/imgn-stock-abbv-stock-biotech-acquisition-elahere/
0
0
11/30/23 at 1:22pm
Organization
Investor's Business Daily
Author
Investor's Business Daily
41 words
0
Comments
IMGN stock soared after AbbVie agreed to buy ImmunoGen for $10.1 billion, offering a rich premium for the maker of cancer drug Elahere.
You are the first to view
Create an account
or login to join the discussion